Author | Year | Country | Type of research | Sample size | Case group/control group | Average age | Male/female | Gold Standard | Sampling type | Threshold | Whether to exclude inflammatory diseases | Whether to set a control group | Prosthesis type | Typology of infection |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Wang [21] | 2020 | China | Retrospective | 157 | 51/106 | 64.6 | 70/87 | MSIS | Serum | 1220Â ng/ml | Yes | Yes | NA | Chronic |
Qin [22] | 2019 | China | Forward-looking | 122 | 55/67 | 65.9 | 53/69 | ICM | Serum | 1170Â ng/ml | Yes | Yes | NA | Chronic |
Pannu [14] | 2020 | USA | Retrospective | 111 | 89/22 | 70 | 62/49 | ICM | Serum | 850Â ng/ml | No | Yes | NA | NA |
Hu [23] | 2020 | China | Retrospective | 77 | 40/37 | 60.8 | 37/40 | MSIS | Serum | 955Â ng/ml | No | Yes | NA | NA |
Shahi [12] | 2017 | USA | Forward-looking | 195 | 86/109 | 59.7 | 101/94 | ICM | Serum | 850Â ng/ml | No | Yes | NA | NA |
Fu [19] | 2019 | China | Forward-looking | 30 | 15/15 | 65.6 | 9/21 | MSIS | Plasma | 850Â ng/ml | Yes | Yes | NA | NA |
Li [13] | 2019 | China | Retrospective | 565 | 95/470 | NA | 248/317 | ICM | Plasma | 1250Â ng/ml | No | Yes | NA | NA |
Huang [20] | 2019 | China | Retrospective | 101 | 31/70 | 64.9 | NA | ICM | Serum | 850Â ng/ml | Yes | Yes | NA | NA |
Xiong [15] | 2019 | China | Forwardlooking | 80 | 26/54 | 65.4 | 54/26 | MSIS | Serum | 756Â ng/ml | Yes | Yes | NA | NA |
Xu [24] | 2019 | China | Retrospective | 318 | 129/189 | NA | NA | ICM | Plasma | 1020Â ng/ml FEU | Yes | Yes | NA | NA |